Neo7Logix COVID-19 Treatment Reduces Viral Infection by More Than 99% in Preclinical Study

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

October 27, 2020

Dr. John Catanzaro, CEO of Neo7Logix USA LLC, today announced that the company has developed an approach to design highly effective specific-matched Anti-Viral Peptide (AVP) sequences that can be used for the treatment and prevention of novel pathogen diseases.

Neo7Logix reports notes a patent-pending method is used to design a pool of synthetic peptides that act in a multi-mechanistic approach to inhibit virus entry points, prevent viral endocytosis (membrane engulfing), block viral unpacking and replication and stimulate the long-term immune response and eradication of the virus.

This “Precision-Based Immuno-Molecular Augmentation (PBIMA)” design method uses artificial intelligence to guide the design of anti-viral peptides based on the target viral genome sequences and available data on the human population HLA (human leukocyte antigen) susceptibility. Neo7Logix has recently completed a preclinical study that demonstrated greater than 99% reduction of viral load in mice infected with mutant coronavirus HCoV-229E using anti-HCoV-229E (COVID-19) PBIMA-SOLVx with no adverse effects. This proof of concept study also revealed remarkable immunomodulatory stimulation of T and B cells for the immune response. Dr. Catanzaro added, “to our knowledge, there currently is no other highly effective treatment for COVID-19.”

The AVP had no Antibody-Dependent Enhancement (ADE) problem because it induced only CD8+/CD4+ response unlike some current prophylactic vaccines in clinical trials.  Existing preclinical data along with computational results show that the AVP designs are non-toxic, non-allergenic and thermostable.

The PBIMA approach can be used to design AVP’s for future novel pathogens in as little as two weeks. Neo7Logix USA LLC is preparing to submit an application to begin clinical trials as soon as possible under the FDA’s Investigational New Drug (IND) program.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.